Reuters logo
BRIEF-Lyndra and Allergan sign a partnership to develop ultra-long-acting oral products
September 7, 2017 / 11:21 AM / 17 days ago

BRIEF-Lyndra and Allergan sign a partnership to develop ultra-long-acting oral products

Sept 7 (Reuters) - Allergan Plc

* Lyndra Inc announced a partnership with Allergan Plc to develop orally administered ultra-long-acting products for treatment of Alzheimer’s disease

* Lyndra - agreement provides $15 million upfront payment to Lyndra along with up to $90 million in development and regulatory milestones Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below